Scribe Therapeutics Inc. Common Stock SCTX
$28.57
-9.86%
at last close
Market Cap$598.00 million
P/E Ratio—
Div Yield—
Volume68.4K
52-Week Range
$17.30$39.60
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $49.00 (+71.5% upside)
Key Stats
- Today's Range
- $28.46 – $31.66
- 50-Day Range
- $17.30 – $39.60
- 52-Week Range
- $17.30 – $39.60
- Volume
- 68K shs
- Average Volume
- 263K shs
- Market Cap
- $598.00 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.39%
- Days to Cover
- 1.34
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
Related Stocks
Compare head-to-head: SCTX vs NVDA·SCTX vs AAPL·SCTX vs GOOGL·SCTX vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.